#USA #Fremont #Alzheimer's Disease #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Launches a Breakthrough Assay for Alzheimer's Research

In a significant advancement for neurological studies, Alamar Biosciences has launched the NULISAqpcr™ BD-pTau217 Assay. This innovative approach represents a pivotal leap in the field of Alzheimer's disease research, providing a non-invasive method to quantify brain-derived phosphorylated tau 217 (pTau217), a critical biomarker associated with Alzheimer's and other tauopathies.

Unveiled on October 9, 2025, the NULISAqpcr BD-pTau217 Assay utilizes Alamar’s proprietary NULISA™ platform, ensuring unparalleled sensitivity and specificity when assessing non-invasive samples such as plasma, serum, and dried blood spots. One of the standout features of this assay is its ability to directly measure pTau217 from the central nervous system (CNS) without the need for cerebrospinal fluid (CSF) collection or complex PET imaging. This breakthrough opens new paths for broader research participation in population studies and long-term clinical trials.

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, expressed excitement about the new assay, stating, "The NULISAqpcr BD-pTau217 Assay redefines what’s possible in CNS biomarker quantitation. By eliminating the peripheral tau sources that can cloud results, researchers can now observe meaningful changes in the brain with greater accuracy and earlier than before."

Neuroscience professionals are already acknowledging the benefits of the new assay. Dr. Jonathan Schott, a professor of neurology at University College London, noted the promising early results from their team. According to him, the assay not only matches the performance of existing plasma pTau217 tests but also demonstrates a higher fold-change and reduces the number of indeterminate results. This feature can be particularly beneficial in the detection of asymptomatic individuals who are likely harboring significant Alzheimer's pathology, making them suitable candidates for clinical trials targeting disease-modifying therapies.

The NULISAqpcr BD-pTau217 Assay can function as a standalone single-plex assay or as part of the multiplex NULISAseq™ CNS Disease Panel 120. Its streamlined workflow allows the processing of over 220 samples daily using the ARGO™ HT System, making it well-suited for high-throughput environments such as disease cohort studies and extensive population-based research.

Alamar Biosciences is actively collaborating with various stakeholders in the neuroscience research community to harness biomarker insights that could fast-track advancements not only in Alzheimer's but potentially across the spectrum of neurodegenerative diseases.

To gain further insights into this revolutionary assay and how it may impact Alzheimer’s research moving forward, visit Alamar’s official website.

Disclaimer: The NULISA BD-pTau217 Assays are intended for research purposes only and are not approved for diagnostic procedures.